Endocrinology, Vol 128, 897-901, Copyright © 1991 by Endocrine Society

ARTICLES

Sexual dimorphism of pancreatic beta-cell degeneration in transgenic mice expressing an insulin-ras hybrid gene

S Efrat
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461.

The human H-ras oncogene induces cell degeneration and diabetes when expressed in pancreatic beta-cells in transgenic mice. The disease develops predominantly in male mice between 5-8 months of age. Most transgenic female mice do not manifest this phenotype, even at much greater ages. However, ovariectomy induces female beta-cell degeneration similar to that in the males. In contrast, castration or the presence of the testicular feminization mutation do not alter the course of the disease in males. Treatment of males and ovariectomized females with estrogen prevents the development of diabetes. These results suggest that testicular androgens and a functional testosterone receptor are not required for the increased susceptibility of male beta- cells to the effects of the Ras oncoprotein, and that the relative resistance of female beta-cells is mediated by estrogen. In addition, a genetic component of female beta-cell resistance to Ras is revealed by crossing the transgenic mice with C3HeB/FeJ mice, which results in a pronounced increase in the incidence of female diabetes.

This article has been cited by other articles:

				H. Zhang, A. M. Ackermann, G. A. Gusarova, D. Lowe, X. Feng, U. G. Kopsombut, R. H. Costa, and M. Gannon The FoxM1 Transcription Factor Is Required to Maintain Pancreatic {beta}-Cell Mass Mol. Endocrinol., August 1, 2006; 20(8): 1853 - 1866. [Abstract] [Full Text] [PDF]

				M Fraenkel, J Caloyeras, S-G Ren, and S Melmed Sex-steroid milieu determines diabetes rescue in pttg-null mice. J. Endocrinol., June 1, 2006; 189(3): 519 - 528. [Abstract] [Full Text] [PDF]

				R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF]

				K. Yamagata, T. Nammo, M. Moriwaki, A. Ihara, K. Iizuka, Q. Yang, T. Satoh, M. Li, R. Uenaka, K. Okita, et al. Overexpression of Dominant-Negative Mutant Hepatocyte Nuclear Factor-1{alpha} in Pancreatic {beta}-Cells Causes Abnormal Islet Architecture With Decreased Expression of E-Cadherin, Reduced {beta}-cell Proliferation, and Diabetes Diabetes, January 1, 2002; 51(1): 114 - 123. [Abstract] [Full Text] [PDF]

				K. A. Hagenfeldt-Johansson, P. L. Herrera, H. Wang, A. Gjinovci, H. Ishihara, and C. B. Wollheim {beta}-Cell-Targeted Expression of a Dominant-Negative Hepatocyte Nuclear Factor-1{alpha} Induces a Maturity-Onset Diabetes of the Young (MODY)3-Like Phenotype in Transgenic Mice Endocrinology, December 1, 2001; 142(12): 5311 - 5320. [Abstract] [Full Text] [PDF]

				E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling Multiple Actions of Steroid Hormones---A Focus on Rapid, Nongenomic Effects Pharmacol. Rev., December 1, 2000; 52(4): 513 - 556. [Abstract] [Full Text] [PDF]

				A. Nadal, J. M. Rovira, O. Laribi, T. Leon-quinto, E. Andreu, C. Ripoll, and B. Soria Rapid insulinotropic effect of 17ß-estradiol via a plasma membrane receptor FASEB J, October 1, 1998; 12(13): 1341 - 1348. [Abstract] [Full Text]